Literature DB >> 3974895

Improvement of abnormal pyruvate metabolism and cardiac conduction defect with coenzyme Q10 in Kearns-Sayre syndrome.

S Ogasahara, S Yorifuji, Y Nishikawa, M Takahashi, K Wada, T Hazama, Y Nakamura, S Hashimoto, N Kono, S Tarui.   

Abstract

In a patient with Kearns-Sayre syndrome, concentration of coenzyme Q10, a component of the mitochondrial electron transport system, was decreased in serum and in the mitochondrial fraction of skeletal muscle. Serum concentrations of lactate and pyruvate were abnormally high, especially after exercise or oral glucose loading. Levels of folic acid in plasma and CSF were decreased. ECG showed a first-degree atrioventricular block. After administration of coenzyme Q10 60 to 120 mg daily for 3 months, serum levels of lactate and pyruvate became normal, with improvement of atrioventricular block and ocular movements.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3974895     DOI: 10.1212/wnl.35.3.372

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  16 in total

1.  Cytochrome c oxidase and coenzyme Q in neuromuscular diseases: a histochemical study.

Authors:  C Doriguzzi; L Palmucci; B Pollo; T Mongini; M Maniscalco; L Chiadò-Piat; D Schiffer
Journal:  Acta Neuropathol       Date:  1990       Impact factor: 17.088

Review 2.  Brain and skeletal muscle bioenergetic failure in familial hypobetalipoproteinaemia.

Authors:  R Lodi; R Rinaldi; A Gaddi; S Iotti; R D'Alessandro; N Scoz; M Battino; V Carelli; G Azzimondi; P Zaniol; B Barbiroli
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-06       Impact factor: 10.154

3.  Spontaneous Kearns-Sayre/chronic external ophthalmoplegia plus syndrome associated with a mitochondrial DNA deletion: a slip-replication model and metabolic therapy.

Authors:  J M Shoffner; M T Lott; A S Voljavec; S A Soueidan; D A Costigan; D C Wallace
Journal:  Proc Natl Acad Sci U S A       Date:  1989-10       Impact factor: 11.205

4.  Coenzyme Q in serum and muscle of 5 patients with Kearns-Sayre syndrome and 12 patients with ophthalmoplegia plus.

Authors:  S Zierz; G Jahns; F Jerusalem
Journal:  J Neurol       Date:  1989-02       Impact factor: 4.849

5.  Activity of 3-hydroxy-3-methylglutaryl-coenzyme A reductase does not respond to ubiquinone uptake in cultured cells.

Authors:  W A Maltese; J R Aprille; R A Green
Journal:  Biochem J       Date:  1987-09-01       Impact factor: 3.857

6.  Clinical improvement after administration of coenzyme Q10 in a patient with mitochondrial encephalomyopathy.

Authors:  S Goda; T Hamada; S Ishimoto; T Kobayashi; I Goto; Y Kuroiwa
Journal:  J Neurol       Date:  1987-01       Impact factor: 4.849

7.  Muscle coenzyme Q deficiency in familial mitochondrial encephalomyopathy.

Authors:  S Ogasahara; A G Engel; D Frens; D Mack
Journal:  Proc Natl Acad Sci U S A       Date:  1989-04       Impact factor: 11.205

Review 8.  Possible mechanisms of the anaerobic threshold. A review.

Authors:  M L Walsh; E W Banister
Journal:  Sports Med       Date:  1988-05       Impact factor: 11.136

9.  Variation in retinal changes and muscle pathology in mitochondriopathies.

Authors:  J Bosche; W Hammerstein; E Neuen-Jacob; R Schober
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1989       Impact factor: 3.117

10.  Targeting the progression of Parkinson's disease.

Authors:  J L George; S Mok; D Moses; S Wilkins; A I Bush; R A Cherny; D I Finkelstein
Journal:  Curr Neuropharmacol       Date:  2009-03       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.